Neuroprotection in Glaucoma: A Review
DOI:
https://doi.org/10.60787/tnhj.v11i2.51Keywords:
Neuroprotection, Glaucoma.Abstract
Background: Glaucoma, globally the second most common cause of blindness and the commonest cause of preventable visual disability, is a progressive neurodegenerative disease of the retinal ganglion cells and their axons .Neuroprotection is an evolving area in the management of glaucoma. This review aims to highlight the current neuroprotective agents under investigation and the promise they hold for future management of glaucoma.
Method: The available literature on the use of Neuroprotection in Glaucoma was reviewed using available journals and internet based search engines such as pubmed and Medline. Keywords employed were Neuroprotection and Glaucoma.
Results: There is ongoing research on neuroprotective agents in management of glaucoma. A few of the currently available anti glaucoma medications also have neuroprotective functions. The mainstay of glaucoma management however remains lowering of intraocular pressure. Nigerian literature on neuroprotection was not available.
Conclusion: It has become increasingly obvious that glaucoma represents a complex multifactorial disease that produces an accelerated rate of ganglion cell atrophy related to a numerous pathogenic mechanisms that not only most certainly involve IOP, but also include defective auto regulation and ischaemia; neurotrophic factor deficiency; glutamate mediated excitotoxicity, immune related phenomenon; intracellular calcium influx and free radical damage3.IOP lowering still remains the mainstay of treatment. Neuroprotection has promise for preventing retinal cell ganglion death independent of IOP.It therefore presents an exciting development in the pursuit for a treatment modality for this debilitating disease.
Downloads
References
Kaushik S, Pandav SS, Ram J.Neuroprotection in glaucoma. Journal of Postgraduate Medicine 2003; 49(1):90-95.
Schwartz M.Neurodegeneration and Neuroprotection in Glaucoma: Development of a Therapeutic Neuroprotective Vaccine. Investigative Ophthalmology and Visual Science 2003; 44:1407-1411.
Vasudevan SK, Gupta V, Crowton JG. Neuroprotection in glaucoma. Indian J Ophthalmol 2011; 59:102-113.
The Advanced Glaucoma Intervention Study (AGIS): Study design and methods and baseline characteristics ofstudy patients. Control Clin Trials 1994; 15: 299-325.
Sommer A. Collaborative normal-tension glaucoma study. Am J Ophthalmol 1999; 128:776-777.
Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M.Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268-79.
Cheunq W, Guo L, Cordeir MF. Neuroprotection in glaucoma: drug-based approaches. Optom Vis Sci 2008; 85(6): 406-416.
Levin LA, Peeples P. History of Neuroprotection and rationale as therapy for glaucoma. Am J Manag Care 2008 Feb; 14(I Suppl): S11-4
Weinreb RN, Levin LA. Is Neuroprotection a viable therapy for glaucoma? Arch Ophthalmol 1999 Nov;117(11):1540-4
Lebrun-Julien F, DiPolo A. Molecular and cell-based approaches for Neuroprotection in glaucoma. Optom Vis Sci.2008 Jun;85(6):417-24
Krupin T. Neuroprotection and Glaucoma. Cited 2010 June 28.Available from http//medscapeCMEOphthalmology.
Wein FB, Levin LA. Current Understanding ofNeuroprotection in glaucoma. Curr Opin Ophthalmol 2002 Apr;13(2):61-7
Chua B, Goldberg I. Neuroprotective Agents in Glaucoma Therapy: Recent Developments and Future Directions. Expert Review of Ophthalmology 2010; 5(5): 627-636.
Hartwick AT. Beyond intraocular pressure: neuroprotective strategies for future glaucoma therapy. Optom Vis Sci. 2001 Feb;18(2):85-94
Osborne NN, Chidlow G, Layton CJ, Wood JP, Casson RJ, Melena J.Optic nerve and Neuroprotection strategies. Eye(Lond) 2004 Nov;18(11):1075-84
Quigley HA. Neuronal death in glaucoma. Prog. Retin. Eye Res. 1999; 18(1): 39-57.
Tamada Y, Nakajima T, Shearer TR, Azuma M. Proteolysis of neuronal cytoskeletal proteins by calpain contributes to rat retinal cell death induced by hypoxia. Brain Res.2005; 1050(1-2):148-155.
Saylor M, McLoon LK, Harrison AR, Lee MS. Experimental and clinical evidence for Brimonidine as an optic nerve and retinal neuroprotective agent: an evidence- based review. Arch. Ophthalmol. 2009; 127(4): 402-406.
Wheeler L, WoldeMussie E, Lai R. Role of alpha 2 agonists in neuroprotection. Surv. Ophthalmol.2003; 48(Suppl 1) S47-S51.
Fitzgerald M, Payne SC, Bartlett CA, Evill L, Harvey AR, Dunlop SA.Secondary retinal ganglion cell death and the neuroprotective effects of the calcium channel blocker lomerizine. Invest. Ophthalmol. Vis. Sci. 2009; 50(11): 5456-5462.
Koseki N, Araie M, Tomidokoro A et al. A placebo- controlled 3- year study of a calcium channel blocker on visual field and ocular circulation in glaucoma with low normal pressure. Ophthalmology.2008; 115(11):2049-2057.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2015 The Nigerian Health Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Journal is owned, published and copyrighted by the Nigerian Medical Association, River state Branch. The copyright of papers published are vested in the journal and the publisher. In line with our open access policy and the Creative Commons Attribution License policy authors are allowed to share their work with an acknowledgement of the work's authorship and initial publication in this journal.
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author.
The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations. While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
TNHJ also supports open access archiving of articles published in the journal after three months of publication. Authors are permitted and encouraged to post their work online (e.g, in institutional repositories or on their website) within the stated period, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). All requests for permission for open access archiving outside this period should be sent to the editor via email to editor@tnhjph.com.
